Cyclacel Pharmaceuticals, Inc.

Symbol: CYCCP

NASDAQ

19.4

USD

Market price today

  • -0.0732

    P/E Ratio

  • -0.0021

    PEG Ratio

  • 2.87M

    MRK Cap

  • 0.00%

    DIV Yield

Cyclacel Pharmaceuticals, Inc. (CYCCP) Financial Statements

On the chart you can see the default numbers in dynamics for Cyclacel Pharmaceuticals, Inc. (CYCCP). Companys revenue shows the average of 0.463 M which is 1.090 % gowth. The average gross profit for the whole period is -1.315 M which is 0.345 %. The average gross profit ratio is -7.949 %. The net income growth for the company last year performance is 0.064 % which equals -0.099 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Cyclacel Pharmaceuticals, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.680. In the realm of current assets, CYCCP clocks in at 7.444 in the reporting currency. A significant portion of these assets, precisely 3.378, is held in cash and short-term investments. This segment shows a change of -0.816% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0.037 in the reporting currency. This figure signifies a year_over_year change of -0.651%. Shareholder value, as depicted by the total shareholder equity, is valued at 0.607 in the reporting currency. The year over year change in this aspect is -0.961%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2.933, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000

balance-sheet.row.cash-and-short-term-investments

30.923.418.336.6
33.4
11.9
17.5
23.9
16.5
20.4
24.2
31.1
16.4
24.4
29.5
11.5
25.7
58.8
54
20.5
47.3
13.5
0
0
0

balance-sheet.row.short-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
1.5
27.8
9.8
6.9
33.4
11.3
0
0
0

balance-sheet.row.net-receivables

16.042.95.63.7
1.3
1.3
1.5
1.5
2.1
3
3.5
0
0
0
0
0
0
2.5
2.5
0
0
0
0
0
0

balance-sheet.row.inventory

-3.220-5.60.6
0.7
0.7
0.6
0.5
1
1
1.1
0
0
0.2
0.2
0.1
0.5
0.2
1.4
0
0
0
0
0
0

balance-sheet.row.other-current-assets

9.021.16.10.1
0.1
0.1
0.2
0.1
0
0.1
0.3
0.6
0.9
1.2
1.4
1.7
2.8
0.6
0.3
0.4
1
0.5
0
0
0

balance-sheet.row.total-current-assets

52.767.424.440.9
35.5
14
19.8
26
19.6
24.6
29
35.2
18.9
25.8
31.1
13.4
29
63.8
58.2
20.9
48.3
14.1
0
0
0

balance-sheet.row.property-plant-equipment-net

0.550.10.20.1
1.3
1.3
0
0
0
0.2
0.4
0.3
0.1
0.2
0.4
0.9
1.7
3
2.1
0.2
6.2
2.8
0
0
0

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
4.6
2.7
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
4.3
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
8.9
2.7
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

6.431.32.91.6
-1.3
-1.3
0
0
0
0
0
0.1
0.4
0
0
0.2
0.2
0.2
0.2
0.3
1.1
1.7
0
0
0

balance-sheet.row.total-non-current-assets

6.981.43.11.6
1.3
1.3
0
0
0
0.2
0.4
0.3
0.5
0.2
0.4
1.1
1.9
12.1
5.1
0.5
7.3
4.4
0
0
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21.5
24.7
28.5

balance-sheet.row.total-assets

59.748.827.542.6
36.8
15.3
19.8
26
19.7
24.8
29.4
35.5
19.4
26
31.5
14.5
31
75.9
63.3
21.4
55.6
18.5
21.5
24.7
28.5

balance-sheet.row.account-payables

9.793.52.62.1
0.5
0.9
2.7
1.6
2.5
1.9
2.8
2.5
2.3
1.8
1.7
1.7
0.8
5
2.2
1.2
1.7
1
0
0
0

balance-sheet.row.short-term-debt

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0
1.6
11.7
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0.2300.10
1.1
1.2
0
0
0
0
0
0
0
0
0
0
0.6
0
0
0
2.7
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.8
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

20.484.64.83.2
2
1.5
1.7
2.6
2.8
3.8
4.7
5
7.1
4.7
4.8
8.1
7.9
9.8
1.4
4
4.1
0.8
0
0
0

balance-sheet.row.total-non-current-liabilities

0.2304.60
1.1
1.2
0.1
0.1
0.1
0.2
0.2
0
0
0
0
0
1.7
3.2
1.4
1.6
4.1
68.6
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
69.7
61
53.9

balance-sheet.row.capital-lease-obligations

0.2300.10
1.1
1.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

30.518.2125.3
3.5
3.6
4.6
4.2
5.4
5.9
7.7
7.5
9.3
6.5
6.5
9.8
10.3
17.9
9.4
6.8
11.5
83.3
69.7
61
53.9

balance-sheet.row.preferred-stock

427.7604.50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

9.0204.50
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-1680.66-428.3-406.2-385
-366.1
-357.6
-349.8
-342.5
-335
-323.2
-308.8
-289.4
-270.3
-257.1
-241.8
-222.3
-202.7
-162.3
-138.3
-155.6
-126.2
-86.6
-68.1
-48.7
-29.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

-4.4-0.9-1.3-0.7
-0.7
-0.8
-0.8
-0.8
-0.7
-0.6
-0.5
-0.1
0
0.1
0
0
0
-2.6
-2.5
-0.2
-1.4
-2.8
0
0
0

balance-sheet.row.other-total-stockholders-equity

1277.51429.8414423
400.1
370.1
365.8
365.1
350.1
342.6
331
317.5
280.2
276.5
266.7
226.9
223.4
222.9
194.7
170.4
171.7
24.5
20
12.4
3.8

balance-sheet.row.total-stockholders-equity

29.230.615.537.3
33.3
11.7
15.3
21.8
14.3
18.8
21.7
28
10
19.5
24.9
4.6
20.6
58
53.9
14.6
44.1
-64.8
-48.1
-36.3
-25.4

balance-sheet.row.total-liabilities-and-stockholders-equity

59.748.827.542.6
36.8
15.3
19.8
26
19.7
24.8
29.4
35.5
19.4
26
31.5
14.5
31
75.9
63.3
21.4
55.6
18.5
21.5
24.7
28.5

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

29.230.615.537.3
33.3
11.7
15.3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

59.74---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
1.5
27.8
9.8
6.9
33.4
11.3
0
0
0

balance-sheet.row.total-debt

0.2300.10
1.1
1.2
0
0
0
0
0
0
0
0
0
0
0.6
0
0.1
2.1
4.2
11.7
0
0
0

balance-sheet.row.net-debt

-30.69-3.3-18.2-36.5
-32.3
-10.7
-17.5
-23.9
-16.5
-20.4
-24.2
-31.1
-16.4
-24.4
-29.5
-11.5
-23.6
-31
-44.1
-11.5
-9.7
9.4
0
0
0

Cash Flow Statement

The financial landscape of Cyclacel Pharmaceuticals, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.226. The company recently extended its share capital by issuing 1.05, marking a difference of -99.978 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0.3 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -6000.000 in the reporting currency. This is a shift of -0.143 from the previous year. In the same period, the company recorded 0.03, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -0.2 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003

cash-flows.row.net-income

-22.55-22.6-21.2-18.9
-8.4
-7.8
-7.3
-7.5
-11.8
-14.3
-19.4
-10.2
-13.2
-15.2
-16
-19.6
-40.4
-24.1
-29.3
-29.4
-39.6
-18.5

cash-flows.row.depreciation-and-amortization

0.03000
0
0
0
0
0.1
0.2
0.2
0.1
0.1
0.2
0.5
0.7
1.9
0.3
1.1
1.5
1.3
0.9

cash-flows.row.deferred-income-tax

-0.61-1.211.5
-0.3
0
0
0
-0.8
0
0
-5.5
0
15.2
0
0.3
6.6
0
0
-1.8
-1.5
0

cash-flows.row.stock-based-compensation

1.471.51.51.2
0.4
0.5
0.3
0.3
0.8
0.7
1.2
0.4
0.4
0.9
1.7
0.8
1.7
0
0
2.2
2.2
0

cash-flows.row.change-in-working-capital

4.955-1.2-0.9
0.1
-2.1
0.2
-0.3
0.8
-1.1
-1
-2
1.5
0.8
-2.6
2.2
-1
0.9
-5.4
-1
1.7
0

cash-flows.row.account-receivables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

0.30.32.62.9
0
-2.2
0.6
-1.5
0.4
-1.5
0
-0.8
1.8
0.6
-3.1
0.5
0
0
0
0.8
0.8
0

cash-flows.row.other-working-capital

4.664.7-3.7-3.8
0
0.1
-0.3
1.2
0.4
0.3
-1
-1.2
-0.2
0.2
0.5
1.7
-1
0.9
-5.4
-1.8
0.9
0

cash-flows.row.other-non-cash-items

0.61.2-1-1.5
0.3
0
0
0
0.8
0.1
0.3
-1
-0.8
-15.9
0.3
0.3
1.3
-0.3
13.4
7
14.8
2.1

cash-flows.row.net-cash-provided-by-operating-activities

-16.11000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.01000
-0.1
0
0
0
0
0
-0.3
-0.2
0
0
0
0
-0.4
-1.8
-0.7
-0.9
-4.4
-1

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
-3.8
0
0
0
0

cash-flows.row.purchases-of-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
-3.1
-153.6
0
-52.3
-80
-30.5

cash-flows.row.sales-maturities-of-investments

0000
0
0
0
0
0
0
0
0
0
0
0
1.5
30.8
136.4
4.6
78.4
57.6
32.8

cash-flows.row.other-investing-activites

0000
0
0
0
0
0
0.1
0.4
5.9
0.1
0
0
0.1
0
0
0
1.5
0
0

cash-flows.row.net-cash-used-for-investing-activites

4.21000
-0.1
0
0
0
0
0.1
0.1
5.7
0.1
0
0
1.6
27.3
-22.7
3.9
26.7
-26.9
1.2

cash-flows.row.debt-repayment

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

1.0513.217.4
29.7
4
0.6
14.7
6.8
11.1
0
27.6
3.9
9.3
33.4
3.8
0
33.5
42.6
0
57.3
0.1

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-0.2-0.2-0.2-0.2
-0.2
-0.2
-0.2
-0.2
-0.2
-0.2
-0.2
-0.3
0
-0.4
0
0
-1.2
-1.2
-0.9
-1.2
0
0

cash-flows.row.other-financing-activites

003.24.6
29.7
4
0
0.2
0
0
12.4
0
0.1
0
0
0
0
-0.1
15.7
-4.3
2.3
12.7

cash-flows.row.net-cash-used-provided-by-financing-activities

0.850.8321.7
29.5
3.8
0.4
14.7
6.6
10.9
12.2
27.3
4
8.9
33.4
3.9
-1.2
32.2
57.4
-5.5
59.6
12.8

cash-flows.row.effect-of-forex-changes-on-cash

0.30.3-0.40
0
0
-0.1
0.1
-0.4
-0.2
-0.5
-0.1
0
0
0.6
-2.9
-3
0.4
0
0
0
0

cash-flows.row.net-change-in-cash

-14.97-15-18.23.2
21.5
-5.6
-6.4
7.4
-3.9
-3.7
-7
14.7
-8
-5
18
-12.7
-6.8
-13.3
41.1
-0.3
11.7
-1.5

cash-flows.row.cash-at-end-of-period

30.923.418.336.6
33.4
11.9
17.5
23.9
16.5
20.4
24.2
31.1
16.4
24.4
29.5
11.5
24.2
31
44.2
13.6
13.9
2.2

cash-flows.row.cash-at-beginning-of-period

45.8918.336.633.4
11.9
17.5
23.9
16.5
20.4
24.2
31.1
16.4
24.4
29.5
11.5
24.2
31
44.2
3.1
13.9
2.2
3.7

cash-flows.row.operating-cash-flow

-16.11-16.1-20.8-18.5
-7.9
-9.4
-6.7
-7.5
-10.1
-14.5
-18.7
-18.2
-12
-14
-16
-15.2
-29.9
-23.1
-20.2
-21.5
-21.1
-15.5

cash-flows.row.capital-expenditure

-0.01000
-0.1
0
0
0
0
0
-0.3
-0.2
0
0
0
0
-0.4
-1.8
-0.7
-0.9
-4.4
-1

cash-flows.row.free-cash-flow

-16.12-16.1-20.8-18.6
-8
-9.5
-6.7
-7.5
-10.1
-14.5
-19
-18.4
-12.1
-14
-16.1
-15.2
-30.3
-24.9
-20.8
-22.4
-25.5
-16.5

Income Statement Row

Cyclacel Pharmaceuticals, Inc.'s revenue saw a change of 0.000% compared with the previous period. The gross profit of CYCCP is reported to be 0.39. The company's operating expenses are 30.69, showing a change of 10.963% from the last year. The expenses for depreciation and amortization are 0.03, which is a -1.133% change from the last accounting period. Operating expenses are reported to be 30.69, which shows a 10.963% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.096% year-over-year growth. The operating income is -30.3, which shows a 0.096% change when compared to the previous year. The change in the net income is 0.064%. The net income for the last year was -22.55.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000

income-statement-row.row.total-revenue

0.420.400
0
0
0.1
0
0.8
1.9
1.7
1.1
0.1
0.7
0.7
0.9
0.9
0.1
0.4
0.8
0.1
0.2
0
0
0.1

income-statement-row.row.cost-of-revenue

0.4000
0
0
0
0
0
0
0
0
0
0.4
0.4
0.5
0.4
19.6
21.2
0
0
0
0
0
0

income-statement-row.row.gross-profit

0.020.400
0
0
0.1
0
0.8
1.9
1.7
1.1
0.1
0.3
0.3
0.4
0.4
-19.4
-20.8
0.8
0.1
0.2
0
0
0.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

19.55---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

6.72---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0.050.11.30.1
0.9
0.2
0.7
0.9
0
0
0
0
0
0.4
6.7
0.9
8.9
21.1
0
7.1
0
0
0
0
0

income-statement-row.row.operating-expenses

26.2730.727.722.9
10.6
9.7
9.7
9.5
15
18.1
24.2
19.1
15.2
16.7
16.5
18.3
34.2
11.5
12.3
30.5
26.6
18
19.6
19.9
13.7

income-statement-row.row.cost-and-expenses

26.2730.727.722.9
10.6
9.7
9.7
9.5
15
18.1
24.2
19.1
15.2
17.1
17
18.8
34.7
31.1
33.5
30.5
26.6
18
19.6
19.9
13.7

income-statement-row.row.interest-income

0.270.30.20
0
0.2
0.3
0.1
0
0
0
0
0
0
0
0.1
1.4
3.6
2.3
1
0.4
0.1
0
0
0

income-statement-row.row.interest-expense

-0.110-20
0
0
0
0
0
0
0
0
0
0
0
0.2
0.3
-0.2
-0.3
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.22-0.11.70.2
1
0.6
0.6
0.9
0.3
-0.3
-0.2
6.1
-0.1
0.5
-0.4
-2.5
-9.4
1.6
-0.4
-7.4
-0.7
0
0
0
0.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0.050.11.30.1
0.9
0.2
0.7
0.9
0
0
0
0
0
0.4
6.7
0.9
8.9
21.1
0
7.1
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-0.22-0.11.70.2
1
0.6
0.6
0.9
0.3
-0.3
-0.2
6.1
-0.1
0.5
-0.4
-2.5
-9.4
1.6
-0.4
-7.4
-0.7
0
0
0
0.6

income-statement-row.row.interest-expense

-0.110-20
0
0
0
0
0
0
0
0
0
0
0
0.2
0.3
-0.2
-0.3
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.010-0.20
0
-0.1
0
0
0.1
0.2
0.2
0.1
0.1
0.2
0.5
0.7
1.9
0.3
1.1
1.5
1.3
0.9
0
0
-0.6

income-statement-row.row.ebitda-caps

-25.77---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-25.85-30.3-27.7-22.9
-10.6
-9.7
-9.5
-9.5
-14.2
-16.2
-22.4
-18
-15.1
-16.4
-16.3
-18.3
-42.2
-32.5
-33.4
-29.7
-26.5
-17.8
-19.6
-19.9
-13.6

income-statement-row.row.income-before-tax

-25.95-30.4-25.9-22.7
-9.7
-9.1
-8.6
-8.5
-13.8
-16.5
-22.6
-11.9
-15.1
-15.8
-16.7
-20.5
-42.1
-26.1
-31.5
-37.1
-27.2
-17.8
0
0
-12.9

income-statement-row.row.income-tax-expense

-3.33-7.8-4.7-3.8
-1.2
-1.3
-1.3
-1
-2
-2.1
-3.2
-1.7
-1.4
-0.6
-0.7
-0.9
-1.7
-2
-2.2
-0.3
13.1
0.6
19.5
19.5
0

income-statement-row.row.net-income

-22.62-22.6-21.2-18.9
-8.4
-7.8
-7.3
-7.5
-11.8
-14.3
-19.4
-10.2
-13.2
-15.2
-16
-19.6
-40.4
-24.1
-29.3
-29.4
-39.6
-18.5
-19.5
-19.5
-12.9

Frequently Asked Question

What is Cyclacel Pharmaceuticals, Inc. (CYCCP) total assets?

Cyclacel Pharmaceuticals, Inc. (CYCCP) total assets is 8805000.000.

What is enterprise annual revenue?

The annual revenue is 47000.000.

What is firm profit margin?

Firm profit margin is 0.058.

What is company free cash flow?

The free cash flow is -18.873.

What is enterprise net profit margin?

The net profit margin is -53.857.

What is firm total revenue?

The total revenue is -61.555.

What is Cyclacel Pharmaceuticals, Inc. (CYCCP) net profit (net income)?

The net profit (net income) is -22555000.000.

What is firm total debt?

The total debt is 37000.000.

What is operating expences number?

The operating expences are 30688000.000.

What is company cash figure?

Enretprise cash is 3378000.000.